Anika Therapeutics | ANIK - Equity Capital And Reserves


Anika Therapeutics reported $133.9M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agenus USD -221.22M 49.89M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Integra LifeSciences USD 1.04B 1.06M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merit Medical Systems USD 1.63B 42.42M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Smith & Nephew USD 5.54B 331M Dec/2025
Stryker USD 22.42B 635M Dec/2025
Veracyte USD 1.34B 34.83M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026